Axsome Therapeutics Inc (AXSM) — Cash Flow-to-Debt Ratio
Axsome Therapeutics Inc (AXSM) has a Cash Flow-to-Debt Ratio of -0.03x as of March 2026, meaning its operating cash flow of $-20.70 Million could theoretically repay 0% of its total liabilities ($659.02 Million) in one year. See Axsome Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Axsome Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Axsome Therapeutics Inc across 13 annual periods. Also explore AXSM year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Axsome Therapeutics Inc (2013–2025)
Year-by-year debt coverage analysis for Axsome Therapeutics Inc. For market capitalisation and broader financial context, see how much is Axsome Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.16x | $-93.41 Million | $601.51 Million | ▲ +38.1% |
| 2024 | -0.25x | $-128.41 Million | $511.48 Million | ▲ +31.3% |
| 2023 | -0.37x | $-145.08 Million | $397.26 Million | ▲ +30.4% |
| 2022 | -0.53x | $-116.51 Million | $221.92 Million | ▲ +65.0% |
| 2021 | -1.50x | $-108.23 Million | $72.15 Million | ▼ -38.3% |
| 2020 | -1.08x | $-78.46 Million | $72.34 Million | ▲ +2.2% |
| 2019 | -1.11x | $-46.38 Million | $41.83 Million | ▲ +46.7% |
| 2018 | -2.08x | $-30.05 Million | $14.44 Million | ▼ -48.1% |
| 2017 | -1.41x | $-26.47 Million | $18.84 Million | ▼ -9.9% |
| 2016 | -1.28x | $-21.28 Million | $16.64 Million | ▲ +54.8% |
| 2015 | -2.83x | $-7.44 Million | $2.63 Million | ▼ -268.3% |
| 2014 | -0.77x | $-4.60 Million | $5.99 Million | ▼ -94.1% |
| 2013 | -0.40x | $-1.63 Million | $4.13 Million | — |